1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Epiomic Epidemiology Series: Aortic Stenosis Forecast in 16 Major Markets 2015-2025

Summary

Black Swan Analysis Epiomic™ Epidemiology Forecast Report on Aortic Stenosis in 16 Major Markets

Aortic Stenosis (AS) is the occlusion or loss of aortic valve surface area resulting in stenosis of the aortic valve. Currently, AS is thought to be the most common form of valvular heart disease in Western countries. This report provides the current prevalent population for AS across 16 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, Turkey, Mexico, Canada, Australia, Finland, Poland, Argentina and China) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the risk factors, aetiology, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of AS have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Aortic Stenosis include:

-Previous myocardial infarct / Angina
-Carotid atherosclerosis
-COPD
-Lower limb atherosclerosis
-Atrial fibrillation
-Heart failure

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

-Able to quantify patient populations in global AS’s market to target the development of future products, pricing strategies and launch plans.
-Gain further insight into the prevalence of the subdivided types of AS and identify patient segments with high potential.
-Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
-Provide a level of understanding on the impact from specific co-morbid conditions on AS’s prevalent population.
-Identify sub-populations within AS which require treatment.
-Gain an understanding of the specific markets that have the largest number of AS patients.

Table Of Contents

Epiomic Epidemiology Series: Aortic Stenosis Forecast in 16 Major Markets 2015-2025
Aortic Stenosis
-List of Tables and Figures
-Introduction
-Cause of the Disease
-Risk Factors and Prevention
-Diagnosis of the Disease
-Variation by Geography/Ethnicity
-Disease Prognosis and Clinical Course
o Management of Aortic Valve Stenosis
-Key Co-morbid Conditions/ Features Associated with the Disease
-Methodology for Quantification of Patient Numbers
o Additional data
-Top-Line Prevalence for Aortic Stenosis
-Features of Aortic Stenosis Patients
o Severity of Aortic Stenosis
o Aetiology of Aortic Stenosis
-Aortic Stenosis by NYHA Class
o Moderate Aortic Stenosis by NYHA Class
o Severe Aortic Stenosis by NYHA Class
-Symptomatic vs. Asymptomatic in Severe Aortic Stenosis
-Associated Co-morbid Conditions of Severe Symptomatic Aortic Stenosis
-Abbreviations used in the Report
-Other Black Swan Analysis Publications
-Black Swan Analysis Online Patient-Based Databases
-Patient-Based Offering
-Online Pricing Data and Platforms
-References
-Appendix


List of Tables
-Classification of Aortic Stenosis severity
-ESC guidelines for management of Aortic Valve Stenosis
-ACC/AHA guidelines for management of Aortic Valve Stenosis
-Prevalence of Aortic Stenosis, total (000s)
-Prevalence of Aortic Stenosis, males (000s)
-Prevalence of Aortic Stenosis, females (000s)
-Severity of stenosis in Aortic Stenosis patients, total (000s)
-AS patients by main aetiology, total (000s)
-Moderate AS patients by NYHA Class, total (000s)
-Severe AS patients by NYHA Class, total (000s)
-Symptomatic vs. asymptomatic in Severe Aortic Stenosis patients, total (000s)
-Prevalence of Diabetes in Severe Symptomatic AS patients, total (000s)
-Prevalence of Dyslipidaemia in Severe Symptomatic AS patients, total (000s)
-Prevalence of Hypertension in Severe Symptomatic AS patients, total (000s)
-Prevalence of COPD in Severe Symptomatic AS patients, total (000s)
-Prevalence of Atrial Fibrillation in Severe Symptomatic AS patients, total (000s)
-Severe Symptomatic AS patients with a history of MI, total (000s)
-Prevalence of Carotid Artery Atherosclerosis in Severe Symptomatic AS patients, total (000s)
-Lower Limb Atherosclerosis in Severe Symptomatic AS patients, total (000s)
-Abbreviations and Acronyms used in the report
-USA Prevalence of Aortic Stenosis by 5-yr age cohort, males (000s)
-USA Prevalence of Aortic Stenosis by 5-yr age cohort, females (000s)
-France Prevalence of Aortic Stenosis by 5-yr age cohort, males (000s)
-France Prevalence of Aortic Stenosis by 5-yr age cohort, females (000s)
-Germany Prevalence of Aortic Stenosis by 5-yr age cohort, males (000s)
-Germany Prevalence of Aortic Stenosis by 5-yr age cohort, females (000s)
-Italy Prevalence of Aortic Stenosis by 5-yr age cohort, males (000s)
-Italy Prevalence of Aortic Stenosis by 5-yr age cohort, females (000s)
-Spain Prevalence of Aortic Stenosis by 5-yr age cohort, males (000s)
-Spain Prevalence of Aortic Stenosis by 5-yr age cohort, females (000s)
-United Kingdom Prevalence of Aortic Stenosis by 5-yr age cohort, males (000s)
-United Kingdom Prevalence of Aortic Stenosis by 5-yr age cohort, females (000s)
-Brazil Prevalence of Aortic Stenosis by 5-yr age cohort, males (000s)
-Brazil Prevalence of Aortic Stenosis by 5-yr age cohort, females (000s)
-Japan Prevalence of Aortic Stenosis by 5-yr age cohort, males (000s)
-Japan Prevalence of Aortic Stenosis by 5-yr age cohort, females (000s)
-Turkey Prevalence of Aortic Stenosis by 5-yr age cohort, males (000s)
-Turkey Prevalence of Aortic Stenosis by 5-yr age cohort, females (000s)
-Mexico Prevalence of Aortic Stenosis by 5-yr age cohort, males (000s)
-Mexico Prevalence of Aortic Stenosis by 5-yr age cohort, females (000s)
-Canada Prevalence of Aortic Stenosis by 5-yr age cohort, males (000s)
-Canada Prevalence of Aortic Stenosis by 5-yr age cohort, females (000s)
-Australia Prevalence of Aortic Stenosis by 5-yr age cohort, males (000s)
-Australia Prevalence of Aortic Stenosis by 5-yr age cohort, females (000s)
-Finland Prevalence of Aortic Stenosis by 5-yr age cohort, males (000s)
-Finland Prevalence of Aortic Stenosis by 5-yr age cohort, females (000s)
-Poland Prevalence of Aortic Stenosis by 5-yr age cohort, males (000s)
-Poland Prevalence of Aortic Stenosis by 5-yr age cohort, females (000s)
-Argentina Prevalence of Aortic Stenosis by 5-yr age cohort, males (000s)
-Argentina Prevalence of Aortic Stenosis by 5-yr age cohort, females (000s)
-China Prevalence of Aortic Stenosis by 5-yr age cohort, males (000s)
-China Prevalence of Aortic Stenosis by 5-yr age cohort, females (000s)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

  • $ 4995
  • Industry report
  • October 2016
  • by GBI Research

Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth Summary Cardiovascular disease (CVD) covers a range of difference ...

Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast-2023

Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...

Peripheral Arterial Disease - Market Insights, Epidemiology and Market Forecast-2023

Peripheral Arterial Disease - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Peripheral Arterial Disease - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Peripheral Arterial ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.